ENTER


Полный размерЗакрыть
Полный размерЗакрыть
Полный размерЗакрыть

1 (06) 2017

The dynamics of cell type uveal melanoma in Kharkiv region for the last 30 years

Details
Details
Category: #1 (06) 2017
Published: Monday, 05 March 2018 15:26
Written by Super User
Hits: 3777

Panchenko M., Honchar O., Prykhodko D., Pereiaslova H.


Kharkiv National Medical University, Kharkiv, Ukraine
Kharkiv Regional Clinical Hospital, Kharkiv, Ukraine

Summary. Uveal melanoma is one of the most common primary intraocular malignancy in adult patients (Mouriaux F., 2014).

The objective of the investigation was to study the dynamics of cell type of uveal melanoma in Kharkiv region in the last 30 years.

Materials and Methods. The results of histological investigations of uveal melanoma were analyzed in 82 patients (33 male and 49 female) aged from 28 to 86 years having been treated in ophthalmology department of Kharkiv regional clinical hospital from 1985 to 2015 years. The cell type tumor was determined according to the modified Callender’s classification.

Results. The conducted research proved, that the average age of the patients was 61.2 years. The spindle cell melanoma was diagnosed in 29 patients (35.4 %), epithelioid cell type was in 24 (29.3 %) and mixed cell type – in 27 (32,9 %). The necrosis of tumor was revealed in two patients. The percentage of patients with epithelioid cells in 1985 – 1994 and in 1995 – 2004 years was about the same (61.9 % and 59.5 % respectively), but in 2005 – 2015 some increase was noticed up to 68.4 %. The comparison of indexes in the periods from 1985 to 2000 and from 2001 to 2015 years proved the increase of epithelioid cells melanoma from 59.6 % to 65 %.

Conclusions. In the last 15 years the increase of epithelioid cells melanoma from 59,6 % to 65 % was fixed in Kharkiv region, and in the last 10 years respectfully – up to 68.4 %. In dynamics in the last 15 years the average age of patients with uveal melanoma increased from 57.8 to 65.6 years in Kharkiv region.

Keywords: uveal melanoma, cell type, dynamics for 30 years.

REFERENCES

  1. Albert D.M. Histopathologic characteristics of uveal melanomas in eyes enucleated from the collaborative ocular melanoma study COMS report no. 6 / D.M. Albert, M. Diener-West, N.L. Robinson [et al.] // Am. J.Ophthalmol. – 1998. – Vol. 125, №6. – P. 745 – 766.
  2. Asnaghi L. EMT-associated factors promote invasive properties of uveal melanoma cells /L. Asnaghi, G. Gezgin, A. Tripathy [et al.] // Mol. Vis. – 2015. – Vol. 21. – P. 919 – 929.
  3. Augsburger J.J. An alternative hypothesis for observed mortality rates due to metastasis after treatment of choroidal melanomas of different sizes / J.J. Augsburger, Z.M. Corrêa, N. Tricho poulos // Trans. Am. Ophthalmol. Soc. – 2007. – Vol. 105. – P. 54 – 60.
  4. Bagger M. The prognostic effect of American Joint Committee on Cancer staging and genetic status in patients with choroidal and ciliary body melanoma / M. Bagger, M.T. Andersen, K.K. Andersen [et al.] // Invest. Ophthalmol. Vis. Sci. – 2015. – Vol. 56. – P. 438 – 444.
  5. Bagger M. Transviteral Retinochoroidal Biopsy Provides a Representative Sample From Choroidal Melanoma for Detection of Chromosome 3 Aberrations / M. Bagger, M.T. Andersen, S. Heegaard [et al.] // Invest. Ophthalmol. Vis. Sci. – 2015. – Vol. 56, 10. – P. 5917 – 5924.
  6. Bergman L. Uveal melanoma survival in Sweden from 1960 to 1998 / L. Bergman, S. Seregard, B. Nilsson [et al.] // Invest. Ophthalmol. Vis. Sci. – 2003. – Vol. 44. – P. 3282 – 3287.
  7. Biswas J. Clinical and Histopathological Characteristics of Uveal Melanoma in Asian Indians. A Study of 103 Patients / J. Biswas, S. Kabra, S. Krishnakumar, M.P. Shanmugam //Indian J. Ophthalmol. – 2004. – Vol. 52. – P. 41 – 44.
  8. Callender G.R. Five hundred melanomas of the choroid and ciliary body followed five years or longer / G.R. Callender, H.C. Wilder, J.E. Ash // Am. J. Ophthalmol. – 1942. – Vol. 25. –P. 962 – 967.
  9. Callender G.R. Malignant melanotic tumors of the eye: a study of histologic types in 111 cases / G.R. Callender // Am. Acad. Ophthalmol. Otolaryngol. – 1931. – Vol. 36. – P. 131 – 140.
  10. Damato B. A reappraisal of the significance of largest basal diameter of posterior uveal melanoma / B. Damato, S.E. Coupland // Eye (Lond.) – 2009. – Vol. 23, 12. – P. 2152 – 2160.
  11. Damato B. Cytogenetics of uveal melanoma: a 7-year clinical experience / B. Damato, C. Duke, S.E. Coupland [et al.] // Ophthalmology – 2007. – Vol. 114. – P. 1925 – 1931.
  12. Damato B. Estimating prognosis for survival after treatment of choroidal melanoma /B. Damato, A. Eleuteri, A.F. Taktak, S.E. Coupland // Prog. Retin. Eye Res. - 2011. - Vol.30.- P. 285 - 295.
  13. Damato B. Legasy of the Collaborative Ocular Melanoma Study / B. Damato // Arch. Ophthalmol. – 2007. – Vol. 125, 7. – P. 966 – 968.
  14. Eskelin S. Tumor doubling times in metastatic malignant melanoma of the uvea: tumor progression before and after treatment / S. Eskelin, S. Pyrhonen, P. Summanen [et al.] //Ophthalmology. – 2000. – Vol. 107. – P. 1443 – 1449.
  15. Field M.G. Resent developments in prognosis and predictive testing in uveal melanoma /M.G. Field, J.W. Harbour // Curr. Opin. Ophthalmol. – 2014. – Vol. 25, 3. – P. 234 – 239.
  16. Fuchs U. An immunohistochemical and prognostic analysis of cytokeratin expression in malignant uveal melanoma / U. Fuchs, T. Kivela, P. Summanen [et al.] // Am. J. Pathol. –1992. – Vol. 141, 1. – P. 169 – 181.
  17. Gupta P.B. The melanocyte differentiation program predisposes to metastasis after neoplastic trans formation / P.B. Gupta, C. Kuperwasser, J.P. Brunet [et al.] // Nat. Genet. – 2005. – Vol. 37. – P. 1047 – 1054.
  18. Harbour J.W. A prognostic test to predict the risk of metastasis in uveal melanoma based on 15-gene expression profile / J.W. Harbour // Methods Mol. Biol. – 2014. – Vol. 1102. –P. 427 – 440.
  19. Harbour J.W. Eye cancer: unique insights into oncogenesis: the Cogan Lecture / J.W. Harbour // Invest.  Ophthalmol. Vis. Sci. – 2006. – Vol. 47. – P. 1736 – 1745.
  20. Hay E.D. The mesenchymal cell, its role in the embryo, and the remarkable signaling mecha nisms that create it / E.D. Hay // Dev. Dyn. – 2005. – Vol. 233. – P. 706 – 720.
  21. Hoek K. Expression profiling reveals novel pathways in the transformation of melanocytes to melanomas / K. Hoek, D.L. Rimm, K.R. Williams [et al.] // Cancer Res. - 2004. - Vol. 64. - P. 5270-5282.
  22. Jensen O.A. Malignant melanomas of the human uvea: 25-year followup of cases in Denmark, 1943–1952 / O.A. Jensen // Acta. Ophthalmol. (Copenh.) – 1982. – Vol. 60. – P. 161 - 182.
  23. Johansson C.C. Expression and prognostic significance of iNOS in uveal melanoma /C.C. Johansson, D. Mougiakakos, E. Trocme [et al.] // Int. J. Cancer. – 2010. – Vol. 126. –P. 2682 – 2689.
  24. Kivela T. Prognostication in eye cancer: the latest tumor, node, metastasis classification and beyond / T. Kivela, E. Kujala // Eye – 2013. – Vol. 27. – P. 243 – 252.
  25. Kujala E. Very long-term prognosis of patients with malignant uveal melanoma / E. Kujala, T. Makitie, T. Kivela // Invest. Ophtalmol. Vis. Sci. – 2003. – Vol. 44. – P. 4651 – 4659.
  26. Laver N.V. Ocular melanoma / N.V. Laver, M.E. McLaughlin, J.S. Duker // Arch. Pathol. Lab. Med. – 2010. – Vol. 134. – P. 1778 – 1784.
  27. Mouriaux F. Increased HIF-1α expression correlates with cell proliferation and vascular markers CD31 and VEGF-A in uveal melanoma / F. Mouriaux, F. Sanschagrin, C. Diorio [et al.] // Invest. Ophthalmol. Vis. Sci. – 2014. – Vol. 55, 3. – P. 1277 – 1283.
  28. Onken M.D. An accurate,clinically feasible multigene expression assay for predicting metastasis in uveal melanoma / M.D. Onken, L.A. Worley, M.D. Tuscan, J.W. Harbour // J. Mol. Diagn. – 2010. – Vol. 12. – P. 461 – 468.
  29. Onken M.D. Gene Expression profiling in uveal melanoma reveals two molecular classes and predicts metastatic death / M.D. Onken, L.A. Worley, J.P. Ehlers, J.W. Harbour // Canser Res. – 2004. – Vol. 64. – P. 7205 – 7209.
  30. Paul E.V. Prognosis of malignant melanomas of the choroid and ciliary body / E.V. Paul, B.L. Parnell, M. Fraker // Int. Ophthalmol. Clin. – 1962. – Vol. 2. – P. 387 – 402.
  31. Polyak K. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits / K. Polyak, R.A. Weinberg // Nat. Rev. Cancer – 2009. – Vol. 9. – P. 265 – 273.
  32. Qu Y. Overexpression of high mobility group A1 protein in human uveal melanomas: implication for prognosis / Y. Qu, Y. Wang, J. Ma [et al.] – Available from: http://journals.plos.org/plosone/article.
  33. Rietschel P. Variates of survival in metastatic uveal melanoma / P. Rietschel, K.S. Pana geas, C. Hanlon [et al.] // J. Clin. Oncol. – 2005. – Vol. 23. – P. 8076 – 8080
  34. Scholes A.G. Monosomy 3 in uveal melanoma: correlation with clinical and histologic predictors of survival / A.G. Scholes, B.E.  Damato, J. Nunn [et al.] // Invest. Ophthalmol. Vis. Sci. – 2003. – Vol. 44. – P. 1008 – 1011.
  35. Shields C.L. Prognosis of uveal melanoma in 500 cases using genetic testing of fine-needle aspiration biopsy specimens / C.L. Shields, A. Ganguly, C.G. Bianciotto [et al.] // Ophthalmology. – 2011. – Vol. 118. – P. 396 – 401.
  36. Sibbritt T. Mapping and significance of the mRNA methylome / T. Sibbritt, H.R.  Patel, T. Preiss // Wiley Interdiscip. Rev. RNA – 2013. – Vol. 15, 4. – P. 397–422.
  37. Singh A.D. Survival rates with uveal melanoma in the United States: 1973–1997 /A.D. Singh, A. Topham // Ophthalmology – 2003. – Vol. 110. – P. 962 – 965.
  38. Singh A.D. Uveal melanoma: trends in incidence, treatment, and survival / A.D. Singh, M.E. Turell, A.K. Topham // Ophthalmology. – 2011. – Vol. 118. – P. 1881 – 1885.
  39. Thiery J.P. Epithelial-mesenchymal transitions in development and disease / J.P. Thiery, H. Acloque, R.Y. Huang, M.A. Nieto // Cell. – 2009. – Vol. 139. – P. 871 – 890.
  40. Toth J. Retrospective study on uveal melanoma / J. Toth // Hungarian Oncology – 2005. –Vol. 49. – P. 19–25.
  41. Triozzi P.L. Targeted therapy for uveal melanoma / P.L. Triozzi, C. Eng, A.D. Singh // Cancer Treat. Rev. - 2008. - Vol. 34. – P. 247 – 258.
  42. Vaarwater J. Multiplex ligation-dependent probe amplification equals fluorescence in situ hybridization for the identification of patients at risk for metastatic disease in uveal melanoma / J. Vaarwater, T. van den Bosch, H.W. Mensink [et al.] // Melanoma Res. – 2012. –Vol. 22. – P. 30 – 37.
  43. Yang J. Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis / J. Yang, R.A. Weinberg // Dev. Cell. – 2008. – Vol. 14. – P. 818 – 829.
  44. Zhang Y. Expression analysis of genes and pathways associated with liver metastases of the uveal melanoma / Y. Zhang, Y. Yang, L. Chen, J. Zhang // BMC Med. Genet. – 2014. – Vol. 15.

Received: 11 Nov. 2016

Published: April 2017

The effect of ectoine on traumatic uveitis course in children

Details
Details
Category: #1 (06) 2017
Published: Monday, 05 March 2018 13:17
Written by Super User
Hits: 4409

Serdyuk V.N.1,2, Klopotskaya N.G.1, Ustimenko S.B.2, Tarnopol’skaya I.N.2, Maydenko E.N.2, Klopotskaya E.P.1


1SE «Dnipropetrovsk Medical Academy of Health Ministry of Ukraine», Dnipro, Ukraine
2CE «Dnipropetrovsk Regional Clinical Ophthalmologic Hospital», Dnipro, Ukraine

Summary. Traumatic uveitis after penetrating eye injury is known to have multifactorial nature: its development is caused by cell membrane destruction, antioxidant enzymes deficiency, accumulation of nitrogen oxidation products, eye hypoxia, release of cytokines in particular interleukins (IL), etc. So use of cytokines inhibitors or blockers is considered to be a perspective way of traumatic uveitis treatment. Researches in recent years showed ability of ectoine to stabilize biological membranes, reduce the IL and prostaglandins production, normalize the nitric oxide level and inhibit cell signaling system.

Aim of the work. To study the effectiveness of ectoine use in the complex treatment of children with traumatic uveitis.

Methods. We observed 14 children of the main group and 10 of the control group with aseptic uveitis after penetrating eye injury. The groups were identical in patients’ age and clinical manifestations. Besides of routine clinical examination we examined the blood level of IL-1 and C-reactive protein (CRP) that is known to be released in liver under the action of IL-1. All the examinations were performed at the 1st and 8th day after trauma. All the children got complex treatment but patients of the main group were prescribed additionally instillations of 2% solution of ectoine (ЕYE-t Ectoine Pro) 8 times per day.

Results. Before treatment the blood levels of IL-1 and CRP in our patients were more than 3.5 times worse than in healthy persons both in the main and the control group. In a week after the therapy had started we observed clinical improvement in the both groups. In the main group IL-1 level decreased from 86.8 ± 4.1 to 52.8 ± 9.1 pg/ml (P<0.005), in the control one from 86.6 ± 5.5 to 77.2 ± 1.3 (P<0.2). Reliability of difference between the groups was P<0,05. CRP level decreased in the main group from 9.8 ± 1.4 to 4.7 ± 0.3 mg/l, in the control one from 9.7 ± 0.6 to 7.1 ± 0.4 (P<0.005). Difference between the groups was reliable (P<0.001). Any allergic reactions and side effects were not observed.

Conclusions. Use of ectoine 2% solution lets improve effectiveness of traumatic uveitis treatment, is safe, pathogenetically reasonable and can be recommended in complex therapy of children with penetrating eye injury.

Keywords: traumatic uveitis, penetrating injury of eye, children, ectoine.

REFERENCES

  1. Gavrilova T.V., Shilov J.I., Chuprina V.V., Lobanova N.L., Chereshneva M.V., Chereshnev V.A. Mechanisms of immune alterations and immunocorrection by myelopeptides under penetrating eye injury. Refraktsionnaya khirurgiya i oftal’mologiya [Refractive Surgery and Ophthalmology]. 2009; (4): 29–35. [in Russian].
  2. Dikinov Z.H., Bashtanenko A.F., Shkalev M.V. Pathogenetic therapy of infectious complications of penetrating eye injury. Immunopatologiya, allergologiya, infektologiya [Immunopathology, Allergology, Infectology]. 2014; (3): 70–74. [in Russian].
  3. Neroev V.V., Chesnokova N.B., Davydova G.A., Davydova N.G., Perova T.S., Stoliarova E.P., Beznos O.V. Effect of the nitric oxide donors NA nitroprusside and L-arginine on the course of uveitis, the antioxidative and antiproteolytic potential of tear and blood in the experiment. Vestnik Oftal’mologii [Messenger of Ophthalmology]. 2007; (3): 22-25. [in Russian].
  4. Rykov S.A., Tumanova O.V., Goncharuk D.V. Analysis of severe eye injuries in children. Ukr. med. chasopis [Ukr. Med. J.]. 2012; (4): 136–139. [in Russian].
  5. Suprun E.V. Perspective of clinical use of interleukin-1 receptor antagonist. Arkhіv klіnіchnoї ta eksperimental’noї meditsini [Arch. Clin. and Exp. Med.]. 2008; (2): 232–238. [in Russian].
  6. Buommino E., Schiraldi Ch., Baroni A., Paoletti I., Lamberti M., Rosa M., Tufano M.A. Ectoine from halophilic microorganisms induces the expression of hsp70 and hsp70B′ in human keratinocytes modulating the proinflammatory response. Cell Stress Chaperones. 2005; (10): 197–203.
  7. Dwivedi M., Brinkkotter M., Harishchandra R.K., Galla H.J. Biophysical investigations of the structure and function of the tear fluid lipid layer and the effect of ectoine. Part B: artificial lipid films. Biochim. et Biophys. Acta. 2014; (10): 2716–2727.
  8. Heba A.A., Wadieb W., Abdallahb D.M., Lentzenc G., Khayyalb M.T. Novel effects of ectoine, a bacteria-derived natural tetrahydropyrimidine, in experimental colitis. Phytomedicine. 2013; (20): 585–591.
  9. Pastor J.M., Salvador M., Argandoña M., Bernal V., Reina-Bueno M., Csonka L.N., Iborra J.L., Vargas C., Nieto J.J., Cánovas M. Ectoines in cell stress protection: Uses and biotechnological production. Biotechnology Advances. 2010; (28): 782–801.
  10. Sydlik U., Gallitz I., Albrecht C., Abel J., Krutmann J., Unfried K. The compatible solute ectoine protects against nanoparticle-induced neutrophilic lung inflammation. Am. J. Respirat. and Critic. Care Med. 2009; (1): 29–35. 

Received: 21 Oct. 2016

Published: April 2017

An analysis comparing the results of treatment of disbinocular amblyopia using a microprism glasses and pleoptic treatment

Details
Details
Category: #1 (06) 2017
Published: Monday, 05 March 2018 10:19
Written by Super User
Hits: 5415

Mellina V., Rykov S.


Shupyk National Medical Academy of Postgraduate Education, Kyiv, Ukraine
Kyiv City Clinical Ophthalmologic Hospital “Center of Eye Microsurgery”, Kyiv, Ukraine

Summary. Application prisms therapy in treating disbinocular amblyopia with conjugated strabismus widely used by foreign ophthalmologists for years. In 2006, Ukraine has been created modified Fresnel microprism and later established manufacturing spheroprismatic glasses lenses for prolonged pleoptortoptical treatment of strabismus, which simultaneously eliminate squint angle and adjust of ametropia.

Objective. Compare the results of treatment of disbinocular amblyopia in children using microprism glasses with traditional hardware pleoptic treatment.

Materials and Methods. In the study involved 149 children with disbinocular amblyopia aged 4 to 18 years. Of those in the study group included 88 children who were treated microprism glasses and 61 children in the control group who underwent pleoptortoptical treatment in view-protection cabinet. Each group of children is divided on the degree of amblyopia in 3 subgroups (weak, medium and high), an average of 30 children in the study and 20 people in the control group. The treatment was 6 months.

Results. The results showed significantly better performance visus amblyopic eye main group opposed to the control. Visual acuity of children increased on average by 38 % and in control of only 12 %. Among them visus in the group with mild degree increased by 28 %, with an average level – 48 %, and high – 43 % as opposed to the control group where the weak - 8.5 %, on average - by 13 % in high - only 6 %.

Conclusions. Thus, treatment of disbinocular amblyopia using microprism glasses much more effectively from traditional pleoptic treatment. Glasses are light and easy to use, have the effect of prolonged ortoptodiploptic due to constant wear and do not require additional hardware techniques.

Keywords: set KK-42, microprism glasses, amblyopia, visual acuity.

REFERENCES

  1. Бутенко Л.В. Створення і застосування високотехнологічних мікропризм Френеля для діагностування та лікування косоокості дітей / Л.В. Бутенко, Л.І. Єгупова // Реєстрація, зберігання і обробка даних. – 2010. – № 1. – С. 67–72.
  2. Жукова О.В. Призматическая коррекция в реабилитации детей с содружественным косоглазием / О.В. Жукова, А.Д. Купцов // Совр. оптометрия. – 2012. – № 1. – С. 33–36.
  3. Малачкова Н.В. Аналіз показників гостроти зору у дітей з діагнозом амбліопія у Вінницькій області за даними ретроспективного аналізу / Н.В. Малачкова // Вісн. Вінниц. нац. мед. ун-ту ім. М.І. Пирогова. – 2012. – № 1. – С. 206–208.
  4. Механизмы нарушения бинокулярного синтеза при амблиопии у детей / С.А. Небера,Л.Н. Бачалдина, И.Н. Гутник, О.А. Антипова. – Иркутск : Изд-во Иркут. гос. ун-та, 2001. – 117 с.
  5. Организация медико-социальной помощи детям с нарушением зрения / Л.А. Жданова, Е.В. Борзов, М.Н. Салова [и др.] // Рос. педиатр. журн. – 2014. – № 1. – С. 49–52.
  6. Сліпота та слабкозорість шляхи профілактики в Україні : довідник лікаря / за ред. С.О. Рикова. – К. Доктор-медіа, 2011. – 265 с.
  7. A randomized trial of increasing patching for amblyopia / D.K. Wallace, E.L. Lazar, J.M. Holmes [et al.] // Ophthalmology. – 2013. – Vol. 120, N 11. – P. 2270–2277.
  8. A randomized trial to evaluate 2 hours of daily patching for strabismic and anisometropic amblyopia in children / D.K. Wallace, A.R. Edwards, S.A. Cotter [et al.] // Ophthalmology. – 2006. – Vol. 113, N 6. – P. 904–912.
  9. Arnold R.W. Amblyopia and strabismus prevalence / R.W. Arnold // Ophthalmology. – 2009. – Vol. 116, N 2. – P. 365–366.
  10. Beyond screening for risk factors: objective detection of strabismus and amblyopia / R.M. Jost, S.E. Yanni, C.L. Beauchamp [et al.] // JAMA. Ophthalmol. – 2014. – Vol. 132, N 7. – P. 814–820.
  11. Childhood amblyopia: current management and new trends / V. Tailor, M. Bossi, J.A. Greenwood, A. Dahlmann-Noor // Br. Med. Bull. – 2016. – Vol. 119, N 1. – P. 75–86.
  12. Husk J.S. Global processing of orientation in amblyopia / J.S. Husk, R.E. Hess // Vision Res. – 2013. – Vol. 82. – P. 22–30.
  13. Kim U.S. Screening for amblyopia / U.S. Kim // Ophthalmology. – 2013. – Vol. 120, N 2. – P. 435–436.
  14. Pai A. Prevalence of amblyopia and strabismus / A. Pai, P. Mitchell // Ophthalmology. – 2010. – Vol. 117, N 10. – P. 2043–2044.
  15. Recurrence of amblyopia after occlusion therapy / R. Bhola, R.V. Keech, P. Kutschke [et al.] // Ophthalmology. – 2006. – Vol. 113, N 11. – P. 2097–2100.
  16. The therapy of amblyopia: an analysis of the results of amblyopia therapy utilizing the pooled data of published studies / J.T. Flynn, J. Schiffman, W. Feuer, A. Corona // Trans. Am. Ophthalmol. Soc. – 1998. – Vol. 96. – P. 431–450.
  17. Vasconcelos G.C. Current treatment of amblyopia: where are we? / G.C. Vasconcelos, M.F. Costa // Arq. Bras. Oftalmol. – 2013. – Vol. 76, N 4. – P. VII–VIII.
  18. Visual acuity, crowding, and stereo-vision are linked in children with and without amblyopia / J.A. Greenwood, V.K. Tailor, J.J. Sloper [et al.] // Invest. Ophthalmol. Vis. Sci. – 2012. – Vol. 53, N 12. – P. 7655–7665
  19. Wong A.M. Amblyopia (lazy eye) in children / A.M. Wong // CMAJ. – 2014. – Vol. 186, N 4. – P. 292.

Received: 16 Jan. 2017

Published: April 2017

Page 3 of 3